Huang-Lian-Jie-Du-Tang inhibits myocardial remodeling in a rat model of metabolic syndrome

Journal of Ethnopharmacology

Volumn 119, Issue 2, 2008, Pages 259-265

  Li, Xiaoxing ^a   Li, Chuanbao ^a   Ji, Xiaoping ^a   Song, Zhaofeng ^a   Wang, Lihong ^a   Zhang, Juan ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cardiac remodeling; Huang Lian Jie Du Tang; Hypertension; Inflammation; Metabolic syndrome

Indexed keywords

CHINESE DRUG; COLLAGEN; COMPLEMENTARY DNA; GENOMIC DNA; HERBACEOUS AGENT; HUANG LIAN JIE DU TANG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; RNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG FORMULATION; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HEART VENTRICLE REMODELING; HERBAL MEDICINE; HISTOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRADITIONAL MEDICINE; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT OUTCOME; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLLAGEN; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; ECHOCARDIOGRAPHY; INFLAMMATION MEDIATORS; MALE; METABOLIC SYNDROME X; MICROSCOPY, ELECTRON, TRANSMISSION; RATS; RATS, WISTAR; RNA, MESSENGER; VENTRICULAR REMODELING;

RATTUS;

EID: 50949106083     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2008.07.019     Document Type: Article

References (27)

1. Abdullah M.M., Xu Z., Pierce G.N., and Moghadasian M.H. The effects of simultaneous administration of dietary conjugated linoleic acid and telmisartan on cardiovascular risks in rats. Lipids 42 (2007) 855-864
2. Arend W.P. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. The Journal of Clinical Investigation 88 (1991) 1445-1451
3. Asbun J., and Villarreal F.J. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. Journal of the American College of Cardiology 47 (2006) 693-700
4. Baker K.M., Booz G.W., and Dostal D.E. Cardiac actions of angiotensin II: role of intracardiac renin-angiotensin system. Annual Review of Physiology 54 (1992) 227-241
5. Bano K.A., and Batool A. Metabolic syndrome, cardiovascular disease and type-2 diabetes. Journal of the Pakistan Medical Association 57 (2007) 511-515
6. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15 (1993) 532-534, 536, 537
7. Crawford D.C., Chobanian A.V., and Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circulation Research 74 (1994) 727-739
8. Dai Y., Miki K., Fukuoka T., Tokunaga A., Tachibana T., Kondo E., and Noguchi K. Suppression of neuropeptides' mRNA expression by herbal medicines in a rat model of peripheral inflammation. Life Sciences 66 (2000) 19-29
9. Di Paola R., Di Guardo G., Lo Giudice P., Caruso V., Magnano C., and Mangiameli S. Preclinical thalassemic cardiopathy: a study by acoustic densitometry. Italian Heart Journal 4 (2003) 413-418
10. Diep Q.N., Benkirane K., Amiri F., Cohn J.S., Endemann D., and Schiffrin E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. Journal of Molecular and Cellular Cardiology 36 (2004) 295-304
11. Groundy, S.M., Brewer, H.B.J., Cleeman, J.I., Smith, S.C.J., Lenfant, C., American Heart Association, National Heart, Lung, and Blood Institute, 2004. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438.
12. Hu C.T., Chang H.R., Hsu Y.H., Liu C.J., and Chen H.I. Ventricular hypertrophy and arterial hemodynamics following deprivation of nitric oxide in rats. Life Sciences 78 (2005) 164-173
13. Lijnen P.J., Petrov V.V., and Fagard R.H. Induction of cardiac fibrosis by transforming growth factor-β(1). Molecular Genetics and Metabolism 71 (2000) 418-435
14. Lin S.C., Lin C.C., Lu F.J., Lin Y.H., and Chen C.H. Protective and therapeutic effects of huanglian-jie-du-tang on hepatotoxin-induced liver injuries. The American Journal of Chinese Medicine 24 (1996) 219-229
15. Mamedov M.N., Gorbunov V.M., Kiseleva N.V., and Oganov R.G. Structural-functional changes of myocardium and hemodynamic disturbances in patients with metabolic syndrome: contribution of arterial hypertension in formation of total coronary risk. Kardiologiia 45 (2005) 11-16
16. Marcy T.R., and Ripley T.L. Aldosterone antagonists in the treatment of heart failure. American Journal of Health-System Pharmacy 63 (2006) 49-58
17. McConnell, K.J., Zadvorny, E.B., Hardy, A.M., Delate, T., Rasmussen, J.R., Merenich, J.A., Clinical Pharmacy Cardiac Risk Service Study Group, 2006. Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program. Pharmacotherapy 26, 1333-1341.
18. McGrath J.C., Deighan C., Briones A.M., Shafaroudi M.M., McBride M., Adler J., Arribas S.M., Vila E., and Daly C.J. New aspects of vascular remodelling: the involvement of all vascular cell types. Experimental Physiology 90 (2005) 469-475
19. Paillole C., Dahan M., Paycha F., Solal A.C., Passa P., and Gourgon R. Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic patients. The American Journal of Cardiology 64 (1989) 1010-1016
20. Ruiz-Ortega M., Lorenzo O., Rupérez M., Blanco J., and Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT (1) and AT (2) receptors. The American Journal of Pathology 158 (2001) 1743-1756
21. Sahn D.J., DeMaria A., and Kisslo J. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
22. Sciarretta S., Ferrucci A., Ciavarella G.M., De Paolis P., Venturelli V., Tocci G., De Biase L., Rubattu S., and Volpe M. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. American Journal of Hypertension 20 (2007) 784-791
23. Shih H.C., Lee T.H., Chen S.C., Li C.Y., and Shibuya T. Anti-hypertension effects of traditional Chinese medicine Ju-Ling-Tang on renal hypertensive rats. American Journal of Chinese Medicine 33 (2005) 913-921
24. Valen G., Yan Z.Q., and Hansson G.K. Nuclear factor κ-B and the heart. Journal of the American College of Cardiology 38 (2001) 307-314
25. Varagic J., Frohlich E.D., Díez J., Susic D., Ahn J., González A., and López B. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. American Journal of Physiology-Heart and Circulatory Physiology 290 (2006) H1503-H1509
26. Weigert J., Neumeier M., Schäffler A., Fleck M., Schölmerich J., Schütz C., and Buechler C. The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Letters 579 (2005) 5565-5570
27. Zhou Q., Rowlands D.K., Gou Y.L., Tsang L.L., Chung Y.W., and Chan H.C. Cardiovascular protective effects of traditional Chinese medicine bak foong pills in spontaneously hypertensive rats. Biological and Pharmaceutical Bulletin 26 (2003) 1095-1099